|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gumusoglu-Acar E, Gunel T, Hosseini MK,
Dogan B, Tekarslan EE, Gurdamar B, Cevik N, Sezerman U, Topuz S and
Aydinli K: Metabolic pathways of potential miRNA biomarkers derived
from liquid biopsy in epithelial ovarian cancer. Oncol Lett.
25:1422023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fantone S, Marzioni D and Tossetta G:
NRF2/KEAP1 signaling inhibitors in gynecologic cancers. Expert Rev
Anticancer Ther. 24:1191–1194. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho KR and Shih Ie M: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mattiske S, Suetani RJ, Neilsen PM and
Callen DF: The oncogenic role of miR-155 in breast cancer. Cancer
Epidemiol Biomarkers Prev. 21:1236–1243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huber O, Bierkamp C and Kemler R:
Cadherins and catenins in development. Curr Opin Cell Biol.
8:685–691. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jeanes A, Gottardi CJ and Yap AS:
Cadherins and cancer: How does cadherin dysfunction promote tumor
progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fletcher DA and Mullins RD: Cell mechanics
and the cytoskeleton. Nature. 463:485–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leung D, Price ZK, Lokman NA, Wang W,
Goonetilleke L, Kadife E, Oehler MK, Ricciardelli C, Kannourakis G
and Ahmed N: Platinum-resistance in epithelial ovarian cancer: An
interplay of epithelial-mesenchymal transition interlinked with
reprogrammed metabolism. J Transl Med. 20:5562022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldie KN, Wedig T, Mitra AK, Aebi U,
Herrmann H and Hoenger A: Dissecting the 3-D structure of vimentin
intermediate filaments by cryo-electron tomography. J Struct Biol.
158:378–385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mendez MG, Kojima S and Goldman RD:
Vimentin induces changes in cell shape, motility, and adhesion
during the epithelial to mesenchymal transition. FASEB J.
24:1838–1851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berek JS, Kehoe ST, Kumar L and
Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum:
2021 FIGO staging system. Int J Gynecol Obstet. 155 (Suppl
1):S61–S85. 2021. View Article : Google Scholar
|
|
19
|
Paul A and Paul S: The breast cancer
susceptibility genes (BRCA) in breast and ovarian cancers. Front
Biosci (Landmark Ed). 19:605–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
21
|
Zuberi M, Mir R, Das J, Ahmad I, Javid J,
Yadav P, Masroor M, Ahmad S, Ray PC and Saxena A: Expression of
serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in
epithelial ovarian cancer and their association with
clinicopathological features. Clin Transl Oncol. 17:779–787. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang W, Wu LR, Li C, Zhou X, Liu P, Jia X,
Chen Y and Zhu W: Five serum microRNAs for detection and predicting
of ovarian cancer. Eur J Obstet Gynecol Reprod Biol X.
3:1000172019.PubMed/NCBI
|
|
23
|
Meng X, Muller V, Milde-Langosch K,
Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic
relevance of circulating exosomal miR-373, miR-200a, miR-200b and
miR-200c in patients with epithelial ovarian cancer. Oncotarget.
7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Panda H, Pelakh L, Chuang TD, Luo X,
Bukulmez O and Chegini N: Endometrial miR-200c is altered during
transformation into cancerous states and targets the expression of
ZEBs, VEGFA, FLT1, IKKbeta, KLF9, and FBLN5. Reprod Sci.
19:786–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Humphries B and Yang C: The microRNA-200
family: Small molecules with novel roles in cancer development,
progression and therapy. Oncotarget. 6:6472–6498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baldi P and Long AD: A Bayesian framework
for the analysis of microarray expression data: Regularized t-test
and statistical inferences of gene changes. Bioinformatics.
17:509–519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sawada K, Mitra AK, Radjabi AR, Bhaskar V,
Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A,
Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer
metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Savagner P: Leaving the neighborhood:
Molecular mechanisms involved during epithelial-mesenchymal
transition. Bioessays. 23:912–923. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Steinert PM and Roop DR: Molecular and
cellular biology of intermediate filaments. Annu Rev Biochem.
57:593–625. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huo Y, Zheng Z, Chen Y, Wang Q, Zhang Z
and Deng H: Downregulation of vimentin expression increased drug
resistance in ovarian cancer cells. Oncotarget. 7:45876–45888.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao D, Dai C and Peng S: Mechanism of the
mesenchymal-epithelial transition and its relationship with
metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shah AS, Scheele WH, Glant MD and Fugere
P: Raloxifene HCl is not stimulatory in the endometrium as assessed
by the blaustein criteria and an estrogenicity scoring system. Prim
Care Update Ob Gyns. 5:1671998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burk U, Schubert J, Wellner U, Schmalhofer
O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression
between ZEB1 and members of the miR-200 family promotes EMT and
invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
